Table 2. Subgroup analyses for PanBio.

	Overall N (%)	Ag-Test positive/ PCR positive N (%)	Ag-Test negative/ PCR positive N (%)	Ag-Test positive/ PCR negative N (%)	Ag-Test negative/ PCR negative N (%)	Sensitivity % (95% CI)	Specificity % (95% CI)
Sensitivity
Overall	1108 (100)	92 (8.3)	14 (1.3)	1 (0.1)	1001 (90.3)	86.8 (79.0–92.0)	99.9 (99.4–100)
Heidelberg	858 (77.4)	44 (5.1)	3 (0.3)	0	811 (94.5)	93.6 (82.8–97.8)	100 (99.5–100)
Berlin	250 (22.6)	48 (19.2)	11 (4.4)	1 (0.4)	190 (76.0)	81.4 (69.6–89.3)	99.5 (97.1–100)
Sampling strategy—Information available for N = 1108
NP swab	1034 (93.3)	91 (8.8)	13 (1.3)	1 (0.1)	929 (89.8)	87.5 (79.8–92.5)	99.9 (99.4–100)
OP swab	74 (6.7)	1 (1.4)	1 (1.4)	0	72 (97.3)	50.0 (25.6–97.4)	100 (94.9–100)
Symptom duration—Information available for N = 687
0–7 days Overall	610 (88.8)	69 (11.3)	7 (1.1)	1 (0.2)	533 (87.4)	90.8 (82.2–95.5)	99.6 (98.9–100)
8–14 days Overall	70 (10.2)	8 (11.4)	5 (7.1)	0	57 (81.4)	61.5 (35.5–82.3)	100 (93.7–100)
Symptomatic versus Asymptomatic—Information available for N = 1100
Symptomatic	712 (64.7)	79 (11.1)	12 (1.7)	1 (0.1)	620 (87.1)	86.8 (78.2–92.3)	99.8 (99.1–100)
Asymptomatic	388 (35.3)	12 (3.1)	2 (0.5)	0	374 (96.4)	85.7 (60.1–96∙0)	100 (99.0–100)
Ct-Value PCR <30 and > = 30—Information available for N = 105*
CT value PCR <30	93 (88)	87 (93.5)	6 (6.5)	NA	NA	93.5 (86.6–97.0)	NA
CT value PCR > = 30	12 (11.0)	4 (33.0)	8 (67.0)	NA	NA	33 (13.8–60.1)	NA
Ct-Value PCR <25 and > = 25—Information available for N = 105*
CT value PCR <25	72 (68.0)	69 (95.8)	3 (4.2)	NA	NA	95.8 (88.5–98.6)	NA
CT value PCR > = 25	33 (31.0)	22 (66.7)	11 (33.3)	NA	NA	66.7 (49.6–80.2)	NA

• One RT-PCR positive with a mutation in the E gene was excluded